ST6GAL1 is upregulated in many malignancies, including ovarian cancer, and its activity regulates epidermal growth factor (EGF) receptor (EGFR) transport dynamics following EGF-induced receptor activation via EGFR sialylation, which enhances cell surface post-activation receptor recirculation, while inhibiting lysosomal degradation to regulate ovarian cancer cells (62). Here, EGF is linked to ovarian carcinoma.